Ascentage Pharma’s Lisaftoclax Gains FDA and EMA Clearance for Global Phase III Trial
Ascentage Pharma Group International (HKG: 6855) announced that it has received clearance from the U.S....
Novo Nordisk’s Wegovy Granted FDA Approval for Metabolic-Associated Steatohepatitis
Danish biopharmaceutical giant Novo Nordisk A/S (NYSE: NVO) announced on August 15, 2025, that its...
Livzon Announces NMPA Acceptance of JP-1366 Tablets Application for Reflux Esophagitis
Livzon Pharmaceutical Group Inc. (HKG: 1513) announced that the drug registration application for its JP-1366...
iRegene Therapeutics’ NouvNeu001 Receives FDA Fast Track Designation for Parkinson’s Therapy
China-based iRegene Therapeutics announced on August 15, 2025, that its self-developed injectable product, NouvNeu001, has...
Ab&B Bio-Tech’s RSV Vaccine Gains IND Approval in China and the U.S.
China-based Ab&B Bio-Tech CO., LTD. JS (HKG: 2627) announced that its self-developed investigational new drug...
Haisco’s HSK39297 Gains NMPA Approval for AMD and gMG Trials
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the National Medical Products Administration (NMPA)...
FDA Accelerates Approval of Dordaviprone for H3 K27M-Mutant Diffuse Midline Glioma
The U.S. Food and Drug Administration (FDA) granted accelerated approval on August 6, 2025, to...
Ajinomoto and Amphastar Ink Licensing Pact for Oncology and wAMD Drug Candidates
Nanjing Ajinomoto Bio-Pharma Services and Amphastar Pharmaceuticals (NASDAQ: AMPH) announced on August 12, 2025, the...
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-7782 Clinical Trials in Advanced Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that its independently developed therapeutic...
FosunInsightec and Shanghai International Medical Center Establish National Focused Ultrasound Demonstration Center
FosunInsightec partnered with the Shanghai International Medical Center (SIMC) on August 11, 2025, to establish...
Minghui Pharmaceutical Secures $131M Pre-IPO Funding Led by OrbiMed and Qiming Ventures
China-based Minghui Pharmaceutical Inc. announced the successful completion of a $131 million Pre-IPO financing round....
FDA Approves Precigen’s Papzimeos for Recurrent Respiratory Papillomatosis”
The U.S. Food and Drug Administration (FDA) has approved Papzimeos (zopapogene imadenovec-drba), developed by Precigen,...
Shanghai Pharmaceuticals and Baxter China Forge Strategic Partnership for Anesthesia Products
Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607) announced the signing of a...
CARsgen Therapeutics Reports 2025 Interim Results and Regulatory Progress
CARsgen Therapeutics Holdings Limited (HKG: 2171) has announced its 2025 Interim Results, highlighting significant progress...
Superluminal Collaborates With Eli Lilly on Small Molecule Therapeutics for Cardiometabolic Diseases
Superluminal Medicines announced on August 14, 2025, a collaboration with Eli Lilly (NYSE: LLY) to...
Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for IgG4-Related Disease by EMA
French pharmaceutical major Sanofi (NASDAQ: SNY) announced that it has received another orphan drug designation...
China’s NHSA Releases Interim Measures for Medical Case-Based Payment Management
The National Healthcare Security Administration (NHSA) issued the “Interim Measures for Medical Security Case-Based Payment...
Pfizer’s Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide
US giant Pfizer Inc. (NYSE: PFE) announced that its Emblaveo (aztreonam and avibactam) has been...
Insilico Medicine’s ISM8969 Nears Clinical Evaluation for Parkinson’s Disease
Insilico Medicine, a Chinese generative AI-driven biotech company, announced the completion of IND-enabling studies for...
SineuGene’s First-in-Class ALS Gene Therapy SNUG01 Gets NMPA Clinical Trial Clearance
Beijing-based SineuGene Therapeutics, a developer of gene therapies for brain disorders based in Beijing, announced that...